Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Drug Supply Delayed as Customers Flock to Place Orders
March 10, 2021
- 70% of Major Products Fall Victim to Off-Year Drug Re-Pricing: Jiho Tally
March 10, 2021
- JCR Terminates Temcell Development for Epidermolysis Bullosa
March 10, 2021
- Top-Tier Drug Makers Face 2-4% Cuts, Mid-Sized Firms 6-8% in Japan’s First Off-Year Re-Pricing: Tally
March 9, 2021
- Top-3 Generic Makers Hit with Average 9.8% Price Cut in Off-Year Revision: Jiho Tally
March 9, 2021
- Rohto Kicks Off Japan PIIa of JAK Inhibitor Delgocitinib for Dry Eye Symptoms
March 9, 2021
- Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec
March 8, 2021
- Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
March 8, 2021
- Japan Ethical Drug Sales Down 5.3% in January: Crecon
March 8, 2021
- Sumitomo Dainippon Ditches Napabucasin, 27 Billion Yen Impairment Loss to Be Incurred in FY2021
March 8, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- Nichi-Iko’s Shipment Halt for 9 APIs Was Due to Biz Suspension
March 5, 2021
- Takeda Takes Back Rare Epilepsy Drug in Revised Deal with Ovid
March 5, 2021
- JCR to Build New Manufacturing Facility for COVID-19 Vaccine
March 5, 2021
- Alesion Top-Selling Drug in February: Encise
March 5, 2021
- Mitsubishi Tanabe Aims for Growth with Global Hopefuls in Pipeline: New Biz Plan
March 5, 2021
- J-TEC Now Consolidated Subsidiary of Teijin
March 4, 2021
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Mitsubishi Tanabe to Launch US Research Center for CNS Drug Discovery
March 4, 2021
- AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…